- |||||||||| Stelara (ustekinumab) / J&J, Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Enbrel (etanercept) / Pfizer, Amgen
Clinical, P2 data, P3 data, Journal: Tildrakizumab: A Review of Phase II and III Clinical Trials. (Pubmed Central) - Feb 29, 2020 Tildrakizumab is efficacious and safe for the treatment of patients with moderate to severe psoriasis. IL-23/p19 inhibitors are a promising class of biological therapy.
- |||||||||| Tremfya (guselkumab) / J&J
Journal: Nummular Dermatitis on Guselkumab for Palmoplantar Psoriasis. (Pubmed Central) - Feb 22, 2020 Histopathology revealed chronic spongiotic dermatitis consistent with a diagnosis of nummular dermatitis. This case highlights a previously unreported adverse event to guselkumab therapy.
- |||||||||| Retrospective data, Review, Journal: Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Feb 14, 2020
Risankizumab appeared to have relatively high efficacy and low risk. The clinical tolerance of other biological agents needs to be further observed.
- |||||||||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Tremfya (guselkumab) / J&J
Clinical, Review, Journal: Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. (Pubmed Central) - Feb 9, 2020 Selectively targeting IL-23p19 may help avoid AEs that have been associated with biologic agents with other mechanisms of action. Data from long-term extension studies and patient registries will further establish the safety profile of IL-23p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice.
- |||||||||| Tremfya (guselkumab) / J&J
Review, Journal: Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. (Pubmed Central) - Feb 8, 2020 Additionally, this medication is well-tolerated, with non-serious infections such as nasopharyngitis and upper respiratory infections (URIs) being the most common adverse events (AEs) reported in its clinical trials. Guselkumab offers yet another effective treatment option in the rapidly growing list of available biological therapies for moderate-to-severe plaque psoriasis.
- |||||||||| Tremfya (guselkumab) / J&J
Journal: Guselkumab (Pubmed Central) - Jan 28, 2020 Guselkumab offers yet another effective treatment option in the rapidly growing list of available biological therapies for moderate-to-severe plaque psoriasis. No abstract available
- |||||||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project (clinicaltrials.gov) - Dec 13, 2019 P=N/A, N=200, Recruiting, Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | N=107 --> 200 | Trial completion date: Jul 2022 --> Dec 2025 | Trial primary completion date: Nov 2020 --> Dec 2024
- |||||||||| Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Tremfya (guselkumab) / J&J
Journal: An emerging role of interleukin-23 in rheumatoid arthritis. (Pubmed Central) - Dec 6, 2019 However, there are very limited clinical studies regarding the use of IL-23 modulators in RA patients. The present review discusses the different aspects of IL-23 including its structural features, signal transduction pathway, preclinical, and clinical role in RA.
- |||||||||| Tremfya (guselkumab) / J&J
Biomarker, Trial initiation date, Trial primary completion date: Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab. (clinicaltrials.gov) - Dec 5, 2019 P1, N=10, Not yet recruiting, The present review discusses the different aspects of IL-23 including its structural features, signal transduction pathway, preclinical, and clinical role in RA. Initiation date: Nov 2019 --> Apr 2020 | Trial primary completion date: Mar 2020 --> Jul 2020
- |||||||||| Tremfya (guselkumab) / J&J
Journal: Guselkumab in the treatment of severe Hidradenitis suppurativa. (Pubmed Central) - Dec 2, 2019 It is known as one of the most life restricting diseases in dermatology with highly negative effects regarding the DLQI. Despite the uprising therapeutic approaches available for HS, there is still a need for more effective medications to treat this auto-inflammational disease.
- |||||||||| Tremfya (guselkumab) / J&J
Journal: Resolution of Guttate Psoriasis Plaques After One-time Administration of Guselkumab (Pubmed Central) - Nov 24, 2019 Patients with chronic plaque psoriasis can also experience guttate flares following streptococcal throat infections.1,2 Controlling guttate psoriasis with topical corticosteroids is difficult to achieve due to numerous widespread lesions. Other treatment options include phototherapy and short term use of cyclosporine or methotrexate, as guttate variants of psoriasis can remit with these treatments.1,2 Guselkumab, an inhibitor of the p19 cytokine subunit of interleukin-23 and interleukin-39, produces dramatic resolutions of plaque psoriasis with long lasting effects.3 This case report describes a patient with a guttate variant of plaque psoriasis that resolved after a single administration of guselkumab and continues to remain clear more than 6 months after treatment with guselkumab.
- |||||||||| Cosentyx (secukinumab) / Novartis
Enrollment closed, Head-to-Head: ARROW: Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab (clinicaltrials.gov) - Nov 15, 2019 P2, N=40, Active, not recruiting, Other treatment options include phototherapy and short term use of cyclosporine or methotrexate, as guttate variants of psoriasis can remit with these treatments.1,2 Guselkumab, an inhibitor of the p19 cytokine subunit of interleukin-23 and interleukin-39, produces dramatic resolutions of plaque psoriasis with long lasting effects.3 This case report describes a patient with a guttate variant of plaque psoriasis that resolved after a single administration of guselkumab and continues to remain clear more than 6 months after treatment with guselkumab. Recruiting --> Active, not recruiting
- |||||||||| Stelara (ustekinumab) / J&J
Review, Journal: IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? (Pubmed Central) - Nov 14, 2019 The approval of ustekinumab, a monoclonal antibody blocking the common p40 subunit of IL12 and IL23, marked an important evolution in medical management for CD: this novel class of biologic therapy demonstrated efficacy in both patients naïve to biologics as well as in patients experiencing inadequate response or loss of response to TNF antagonists...In CD, phase II trials of monoclonal antibodies targeting IL23, including risankizumab and brazikumab, have shown promising results, with multiple agents now entering phase II or phase III studies. In this review, we summarize the current evidence for both anti-IL12/23p40 and anti-IL23p19 monoclonal antibodies in CD.
- |||||||||| Journal: Drugs for psoriasis. (Pubmed Central) - Nov 13, 2019
In this review, we summarize the current evidence for both anti-IL12/23p40 and anti-IL23p19 monoclonal antibodies in CD. No abstract available
- |||||||||| Tremfya (guselkumab) / J&J
Enrollment open: Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP) (clinicaltrials.gov) - Oct 29, 2019 P2, N=15, Recruiting, Treatment of EP should be based on the severity of the clinical scenario as well as patient comorbidities. Not yet recruiting --> Recruiting
- |||||||||| Journal: IL-23 inhibitors for moderate-to-severe psoriasis. (Pubmed Central) - Oct 25, 2019
Pivotal trials in the development of these agents and clinical use of the approved agents are discussed. Thus far, this class of medications seems to provide a high level of efficacy, along with infrequent dosing and very favorable safety results.
- |||||||||| Tremfya (guselkumab) / J&J
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study (Hall B5) - Oct 19, 2019 - Abstract #ACRARHP2019ACR_4195; In pts with active PsA, GUS Q4W and Q8W significantly improved joint and skin symptoms, physical function, and quality of life, and resolved enthesitis/dactylitis. GUS Q4W significantly reduced radiographic damage progression vs. PBO.
- |||||||||| Tremfya (guselkumab) / J&J
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study (Hall B5) - Oct 19, 2019 - Abstract #ACRARHP2019ACR_4185; In pts with active PsA, GUS Q4W and Q8W significantly improved joint and skin symptoms, physical function, and quality of life, and resolved enthesitis/dactylitis. GUS Q4W significantly reduced radiographic damage progression vs. PBO.
|